Press releases
GSK statement on tender offer to acquire Human Genome Sciences
GSK today commented on Human Genome Sciences Board of Directors' decision to recommend against GSK’s tender offer to acquire all of the outstanding shares of HGS for US$13.00 per share in cash.
GlaxoSmithKline completes transaction to increase its ownership in Theravance
Following approval by Theravance, Inc.'s stockholders at their Annual Meeting held on 15 May 2012, GSKs acquisition of 10,000,000 shares of Theravance common stock has now completed.
GlaxoSmithKline to fully acquire Cellzome for £61 million
GSK today announced that it has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for £61 million (US$99 million) in cash.
GSK statement on BBC Panorama broadcast: ‘the truth about tax’
GSK issued the following statement in response to the BBC Panorama programme related to Corporation Tax payments in the UK and Luxembourg broadcast tonight, Monday 14 May 2012.
Stiefel receives US FDA approval of Fabior™ Foam, 0.1%
Stiefel, a GSK company, today announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%.
GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
GSK today announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences for US$13.00 per share in cash.
GSK to commence tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
GSK today announced that it will not participate in Human Genome Sciences strategic alternatives review process and will instead commence a tender offer this week to acquire all of the outstanding shares of HGS for US$13.00 per share in cash.
James Shannon named GlaxoSmithKline Chief Medical Officer
James Shannon has been named GSK’s Chief Medical Officer (CMO), effective 1 May. James will report to R&D Chairman Moncef Slaoui and be based in London. He will be accountable for medical governance and patient safety for all of GSK: Pharmaceuticals, Consumer Healthcare, Vaccines and the global businesses.
GlaxoSmithKline plc appoints two Non-Executive Directors to its Board
GSK announces that Ms. Lynn Elsenhans and Ms. Jing Ulrich will join the Board of the Company with effect from 1 July 2012 as Non-Executive Directors.
GlaxoSmithKline and Yale University establish drug discovery collaboration to design potential new class of medicines
GlaxoSmithKline plc (GSK) and Yale University have established a drug discovery research collaboration to design a potential new class of medicines that degrade disease-causing proteins.
